Fougera gets FDA approval for generic Dovonex

MELVILLE, N.Y. The Food and Drug Administration has granted approval to Fougera for its generic version of the Warner-Chilcott’s psoriasis drug Dovonex. The drug is indicated to treat chronic, moderately severe psoriasis of the scalp.

The generic, calcipotriene topical solution 0.005 percent is available in a 60 mL bottle.

According to Warner-Chilcott, Dovonex had sales of $145.3 million in 2007.

“Fougera has received more FDA approvals for topical products during the past seven years than any other generic company. Today’s announcement that we are first-to-market with Calcipotriene topical solution is another example of our ongoing commitment to provide safe, effective and affordable options to health care providers and their patients,” stated David Klaum, Fougera's senior vice president of commercial business operations.